title: A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine.
abstract: BACKGROUND
  In our previous study, a triple therapy using tripotassium dicitrato bismuthate (TDB), josamycin and furazolidone achieved a suboptimal cure rate of Helicobacter pylori infection.
  
  
  OBJECTIVE
  To investigate whether the addition of an antisecretory agent raises the cure rate using this regimen.
  
  
  METHODS
  One hundred and twenty H. pylori positive patients with peptic ulcer disease or functional dyspepsia were randomly assigned to receive 1-week quadruple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d., josamycin 1000 mg b.d. and famotidine 20 mg b.d. (BFJF group), or triple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. (BFC group). H. pylori status was assessed by histology and culture of gastric biopsy specimens before and at least 4 weeks after completion of therapy.
  
  
  RESULTS
  Seven patients (three in the BFJF group and four in the BFC group) dropped out. Eradication rates (intention-to-treat/per protocol) were 90%/95% in the BFJF group and 82%/88% in the BFC group, respectively (P > 0.05). Duodenal ulcer healing rates were 94% (16/17) in the BFJF group and 80% (20/25) in the BFC group, respectively (P > 0.05). Mild side-effects occurred in 11 (18%) patients in the BFJF group and 10 (17%) in the BFC group (P > 0.05).
  
  
  CONCLUSIONS
  One-week quadruple therapy consisting of TDB, furazolidone, josamycin and famotidine achieves a high cure rate of H. pylori infection.
authors.affiliation: Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Second Medical University, China. liuwzmd@online.sh.cn
authors.forename: W Z
authors.initials: WZ
authors.lastname: Liu
authors.forename: S D
authors.initials: SD
authors.lastname: Xiao
authors.forename: P J
authors.initials: PJ
authors.lastname: Hu
authors.forename: H
authors.initials: H
authors.lastname: Lu
authors.forename: Y
authors.initials: Y
authors.lastname: Cui
authors.forename: G N
authors.initials: GN
authors.lastname: Tytgat
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy; D015738:Famotidine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005664:Furazolidone / Q000008:administration & dosage / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D015570:Josamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D005664:Furazolidone; D015738:Famotidine; C002791:bismuth tripotassium dicitrate; D015570:Josamycin